*Department of Clinical Pharmacy, University Hospital Ostrava, Ostrava, Czech Republic;

†Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic;

‡Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic;

§Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic;

¶Masaryk Memorial Cancer Institute, Brno, Czech Republic; and

║Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic.

Correspondence: Jan Juřica, PharmD, PhD and Ondřej Peš, MSc, PhD, Department of Pharmacology, Faculty of Medicine, Kamenice 62500 Brno, Czech Republic (e-mails: [email protected]; [email protected]).

This publication was written with the support of Specific University Research (MUNI/A/1580/2023, MUNI/A/1564/2023) provided by the Ministry of Education, Youths, and Sports of the Czech Republics and by funds from the Faculty of Medicine, Masaryk University, Czech Republic, to a junior researcher, J. Gregorová (ROZV/28/LF10/2020).

J. Gregorová received honoraria for lectures and consultations from Angelini Pharma (Czech Republic) and Leram Czech. The remaining authors declare no conflicts of interest.

The funder had no role in the design of the review protocol; collection, analyses, or interpretation of data; writing of the manuscript; or decision to publish the results.

The need for patient consent was waived because of the retrospective nature of this study.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.drug-monitoring.com).